LivaNova Q1 2025: Strong Earnings, Innovation Push

LivaNovas Q1 2025 earnings showcase strength, with a 9% increase in revenue to $317 million, driven by cardiopulmonary and neuromodulation segments. Operating income surged to $65 million, and adjusted EPS rose to $0.88. Cardiopulmonary sales jumped 15% due to Essenz rollouts and oxygenator gains. The OSPREY trial for sleep apnea showed promising results, and the company is advancing depression therapy data. Despite a $360 million liability from Italian court litigation, LivaNova boosted full-year organic revenue guidance to 7-8% and EPS to $3.60-$3.70. The company is well-positioned for steady growth. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2a90986726640d2d